[{"orgOrder":0,"company":"Vaginal Biome Science","sponsor":"Aimee Eyvazzadeh","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hetastarch","moa":"None","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Vaginal Biome Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Suppository","sponsorNew":"Vaginal Biome Science \/ Aimee Eyvazzadeh","highestDevelopmentStatusID":"6","companyTruncated":"Vaginal Biome Science \/ Aimee Eyvazzadeh"}]

Find Clinical Drug Pipeline Developments & Deals for Hetastarch

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vaginal Biome Science

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Vaginal Biome Science

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2022

                          Lead Product(s) : Hetastarch

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Aimee Eyvazzadeh

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank